Yi Kijong, Min Kyueng-Whan, Wi Young Chan, Kim Yeseul, Shin Su-Jin, Chung Min Sung, Jang Kiseok, Paik Seung Sam
Department of Pathology, Hanyang University College of Medicine, Seoul, Korea.
Department of Surgery, Hanyang University College of Medicine, Seoul, Korea.
J Breast Cancer. 2017 Dec;20(4):361-367. doi: 10.4048/jbc.2017.20.4.361. Epub 2017 Dec 19.
Wnt7a is a glycoprotein involved in embryonic development and the progression of different types of malignant tumors. This study aimed to detect the level of Wnt7a expression in breast cancer and explore its role in the disease progression and prognosis.
A total of 258 patients diagnosed with invasive ductal carcinoma of the breast were included in this study. Using tissue microarray and immunohistochemical staining, we evaluated the association between Wnt7a expression and clinicopathological parameters, and the prognostic value of Wnt7a.
Wnt7a expression was significantly correlated with estrogen receptor (ER) expression (odds ratio, 3.95; 95% confidence interval [CI], 1.99-7.80; <0.001). On univariate and multivariate analyses, loss of Wnt7a expression was associated with poor disease-free survival (DFS) (multivariate hazard ratio [HR], 9.12; 95% CI, 1.80-46.09; =0.008), but not with poor overall survival (OS). In the ER-positive group (n=114), loss of Wnt7a expression was an independent prognostic factor for shorter DFS (multivariate HR, 13.54; 95% CI, 1.11-165.73; =0.042) and OS (multivariate HR, 4.76; 95% CI, 1.29-17.61; =0.019) on univariate and multivariate analyses. However, in the ER-negative group, there was no significant difference in DFS and OS according to Wnt7a expression.
The loss of Wnt7a expression might be a meaningful factor in assessing DFS and OS, especially in ER-positive breast cancer.
Wnt7a是一种参与胚胎发育及不同类型恶性肿瘤进展的糖蛋白。本研究旨在检测乳腺癌中Wnt7a的表达水平，并探讨其在疾病进展及预后中的作用。
本研究纳入了258例诊断为乳腺浸润性导管癌的患者。采用组织芯片和免疫组化染色，我们评估了Wnt7a表达与临床病理参数之间的关联，以及Wnt7a的预后价值。
Wnt7a表达与雌激素受体（ER）表达显著相关（优势比，3.95；95%置信区间[CI]，1.99 - 7.80；<0.001）。单因素和多因素分析显示，Wnt7a表达缺失与无病生存期（DFS）较差相关（多因素风险比[HR]，9.12；95% CI，1.80 - 46.09；=0.008），但与总生存期（OS）较差无关。在ER阳性组（n = 114）中，单因素和多因素分析显示，Wnt7a表达缺失是DFS缩短（多因素HR，13.54；95% CI，1.11 - 165.73；=0.042）和OS缩短（多因素HR，4.76；95% CI，1.29 - 17.61；=0.019）的独立预后因素。然而，在ER阴性组中，根据Wnt7a表达情况，DFS和OS无显著差异。
Wnt7a表达缺失可能是评估DFS和OS的一个有意义的因素，尤其是在ER阳性乳腺癌中。
